1. Home
  2. VBNK vs MNMD Comparison

VBNK vs MNMD Comparison

Compare VBNK & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VBNK
  • MNMD
  • Stock Information
  • Founded
  • VBNK 1980
  • MNMD 2019
  • Country
  • VBNK Canada
  • MNMD United States
  • Employees
  • VBNK N/A
  • MNMD N/A
  • Industry
  • VBNK Commercial Banks
  • MNMD Pharmaceuticals and Biotechnology
  • Sector
  • VBNK Finance
  • MNMD Health Care
  • Exchange
  • VBNK Nasdaq
  • MNMD Nasdaq
  • Market Cap
  • VBNK 441.5M
  • MNMD 418.7M
  • IPO Year
  • VBNK 2021
  • MNMD N/A
  • Fundamental
  • Price
  • VBNK $9.05
  • MNMD $5.34
  • Analyst Decision
  • VBNK Strong Buy
  • MNMD Strong Buy
  • Analyst Count
  • VBNK 3
  • MNMD 9
  • Target Price
  • VBNK $19.00
  • MNMD $25.75
  • AVG Volume (30 Days)
  • VBNK 77.0K
  • MNMD 1.2M
  • Earning Date
  • VBNK 03-05-2025
  • MNMD 03-06-2025
  • Dividend Yield
  • VBNK 0.73%
  • MNMD N/A
  • EPS Growth
  • VBNK N/A
  • MNMD N/A
  • EPS
  • VBNK 0.89
  • MNMD N/A
  • Revenue
  • VBNK $75,813,751.00
  • MNMD N/A
  • Revenue This Year
  • VBNK $31.26
  • MNMD N/A
  • Revenue Next Year
  • VBNK $40.97
  • MNMD N/A
  • P/E Ratio
  • VBNK $13.99
  • MNMD N/A
  • Revenue Growth
  • VBNK N/A
  • MNMD N/A
  • 52 Week Low
  • VBNK $9.48
  • MNMD $5.03
  • 52 Week High
  • VBNK $18.38
  • MNMD $12.22
  • Technical
  • Relative Strength Index (RSI)
  • VBNK 26.02
  • MNMD 32.08
  • Support Level
  • VBNK $9.76
  • MNMD $5.33
  • Resistance Level
  • VBNK $10.41
  • MNMD $6.06
  • Average True Range (ATR)
  • VBNK 0.31
  • MNMD 0.36
  • MACD
  • VBNK 0.03
  • MNMD -0.10
  • Stochastic Oscillator
  • VBNK 4.30
  • MNMD 0.52

About VBNK VersaBank

VersaBank is a Canadian Schedule I chartered bank with a difference. It has 3 operating segments: Digital Banking Canada, Digital Banking USA and DRTC. It's, cloud-based, business-to-business deposit and lending model provides valued-added solutions to Canadian financial intermediary partners, enabling them to focus on growing their own businesses faster and more profitably. It obtains all of its deposits and provides the majority of its loans and leases electronically, with deposit and lending solutions for financial intermediaries that allow them to excel in their core businesses. In addition, leveraging its internally developed IT security software and capabilities, Company established a wholly owned, subsidiary. Geographically located in Canada and USA.

About MNMD Mind Medicine (MindMed) Inc.

Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).

Share on Social Networks: